<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02545530</url>
  </required_header>
  <id_info>
    <org_study_id>KLD2015.0203</org_study_id>
    <nct_id>NCT02545530</nct_id>
  </id_info>
  <brief_title>Transdermal Clonidine in Chronic Hemodialysis Patients</brief_title>
  <official_title>Transdermal Clonidine on Blood Pressure of Chronic Hemodialysis Patients: A Randomized Crossover Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The majority of chronic hemodialysis patients need a combination of several antihypertensive
      drugs for adequate BP control. The primary objective of this study is to evaluate whether
      transdermal clonidine can improve blood pressure control or decrease oral antihypertensive
      agents type or dosage and the secondary objective is to observe incidence of adverse
      reactions of transdermal clonidine in chronic hemodialysis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It's a randomised crossover clinical trial. Subjects: chronic hemodialysis patients. All
      subjects will be randomised to 2 groups. Subjects in first group will receive 4 weeks
      transdermal clonidine plus regular antihypertensive agents treatments first, 2weeks wash-out
      then and 4 weeks antihypertensive agents without transdermal clonidine. The other group will
      receive 4 weeks antihypertensive agents without transdermal clonidine first, 2weeks wash-out
      then and 4 weeks transdermal clonidine plus regular antihypertensive agents treatments.
      Ambulatory blood pressure, echocardiography, and biochemistry will be detected.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes of blood pressure and oral antihypertensive agents' dosage and type</measure>
    <time_frame>4 weeks</time_frame>
    <description>mmHg of MAP decreased, changes of total antihypertensive agents' DDD and changes of total antihypertensive agents' types</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse effects compared with control group</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Renal Dialysis</condition>
  <arm_group>
    <arm_group_label>transdermal clonidine+</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>apply one transdermal clonidine(2.5mg) each week for 4 weeks besides regular antihypertensive agents, reduce oral antihypertensive agents' dosage or type if blood pressure decreased.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>transdermal clonidine-</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>regular antihypertensive treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>transdermal clonidine</intervention_name>
    <description>2.5mg/patch per week</description>
    <arm_group_label>transdermal clonidine+</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. signed informed consent;

          2. age: 18years to 80 years old；

          3. on hemodialysis for more than or equal to 3 months, not less than 3 times and 12 hours
             hemodialysis per week；

          4. cardiac function grade I or grade II(NYHA)；

          5. Using 1 or more than 1 oral antihypertensive drugs, pre-dialysis systolic blood
             pressure over 140mmHg or dialysis blood pressure over 90mmHg, post-dialysis systolic
             blood pressure over 130mmHg or diastolic blood pressure over 80mmHg

        Exclusion Criteria:

          1. acute infection within 1 month；

          2. acute myocardial infarction/cardiac function grade IV/stroke within 3months；

          3. LVEF lower than 50% by echocardiography；

          4. Dry weight is not suitable by BCM evaluation, more than plus or minus 1kg；

          5. Inter-dialysis weight gain exceeds 5% of dry weight；

          6. Post-dialysis systolic blood pressure lower than 120mmHg and diastolic blood pressure
             lower than 70mmHg；

          7. Begin or stop recombinant human erythropoietin treatment within 2 weeks before
             inclusion or 10 weeks after inclusion;

          8. Adjust recombinant human erythropoietin dosage to more than 2times or less than half
             original dosage within 2 weeks before inclusion or 10 weeks after inclusion；

          9. The treatment regimen will be amended within 10 weeks and it is expected that the
             treatment amendment may affect blood pressure；

         10. Pregnancy or lactation or planning a pregnancy in 10 weeks；

         11. Expected to withdraw hemodialysis treatment in 10 weeks；

         12. Allergic to clonidine or its accessories；

         13. Undergoing other clinical studies, and the research interventions have an impact on
             blood pressure；

         14. Other clinical conditions that may affect the results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Zuo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li ZUO, MD</last_name>
    <phone>+861088324008</phone>
    <email>zuolimd@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liangying Gan, MD</last_name>
    <phone>+861088324005</phone>
    <email>ganl@bjmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zuo, MD</last_name>
      <phone>+861088324008</phone>
      <email>zuolimd@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Liangying Gan, MD</last_name>
      <phone>+861088324005</phone>
      <email>Ganl@bjmu.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2015</study_first_submitted>
  <study_first_submitted_qc>September 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2015</study_first_posted>
  <last_update_submitted>September 7, 2015</last_update_submitted>
  <last_update_submitted_qc>September 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Li Zuo</investigator_full_name>
    <investigator_title>Head of department of nephrology</investigator_title>
  </responsible_party>
  <keyword>renal dialysis</keyword>
  <keyword>hypertension</keyword>
  <keyword>clonidine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

